1). In the dose-escalation part of this phase 1b study, Mouse monoclonal to CHD3 vidutolimod was administered intratumorally at escalating doses with intravenous pembrolizumab to
1). In the dose-escalation part of this phase 1b study, Mouse monoclonal to CHD3 vidutolimod was administered intratumorally at escalating doses with intravenous pembrolizumab to